Soleno Therapeutics Inc (NASDAQ: SLNO)’s stock price has plunge by -15.22relation to previous closing price of 69.64. Nevertheless, the company has seen a -13.51% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-03-27 that Soleno’s shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Is It Worth Investing in Soleno Therapeutics Inc (NASDAQ: SLNO) Right Now?
Moreover, the 36-month beta value for SLNO is -2.37. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLNO is 35.80M and currently, short sellers hold a 13.93% of that float. On April 09, 2025, SLNO’s average trading volume was 1.04M shares.
SLNO’s Market Performance
SLNO stock saw an increase of -13.51% in the past week, with a monthly gain of 35.16% and a quarterly increase of 28.63%. The volatility ratio for the week is 11.08%, and the volatility levels for the last 30 days are 7.11% for Soleno Therapeutics Inc (SLNO). The simple moving average for the past 20 days is 1.68% for SLNO’s stock, with a 18.63% simple moving average for the past 200 days.
Analysts’ Opinion of SLNO
Many brokerage firms have already submitted their reports for SLNO stocks, with Stifel repeating the rating for SLNO by listing it as a “Buy.” The predicted price for SLNO in the upcoming period, according to Stifel is $74 based on the research report published on March 05, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see SLNO reach a price target of $74. The rating they have provided for SLNO stocks is “Buy” according to the report published on December 02nd, 2024.
Robert W. Baird gave a rating of “Outperform” to SLNO, setting the target price at $72 in the report published on December 02nd of the previous year.
SLNO Trading at 13.89% from the 50-Day Moving Average
After a stumble in the market that brought SLNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.22% of loss for the given period.
Volatility was left at 7.11%, however, over the last 30 days, the volatility rate increased by 11.08%, as shares surge +31.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.13% upper at present.
During the last 5 trading sessions, SLNO fell by -13.51%, which changed the moving average for the period of 200-days by +44.74% in comparison to the 20-day moving average, which settled at $58.07. In addition, Soleno Therapeutics Inc saw 31.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLNO starting from Hirano Patricia C, who sale 3,782 shares at the price of $70.11 back on Apr 01 ’25. After this action, Hirano Patricia C now owns 27,036 shares of Soleno Therapeutics Inc, valued at $265,156 using the latest closing price.
PATRICIA HIRANO, the Officer of Soleno Therapeutics Inc, proposed sale 3,782 shares at $70.11 during a trade that took place back on Apr 01 ’25, which means that PATRICIA HIRANO is holding shares at $265,156 based on the most recent closing price.
Stock Fundamentals for SLNO
The total capital return value is set at -0.59. Equity return is now at value -87.35, with -68.74 for asset returns.
Based on Soleno Therapeutics Inc (SLNO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.31. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -796.35.
The liquidity ratio also appears to be rather interesting for investors as it stands at 15.68.
Conclusion
To wrap up, the performance of Soleno Therapeutics Inc (SLNO) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
